CoChat

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study

Open access
Olmos, David, Brewer, Daniel, Clark, Jeremy, Danila, Daniel C, Parker, Chris, Attard, Gerhardt, Fleisher, Martin, Reid, Alison HM, Castro, Elena, Sandhu, Shahneen K, Barwell, Lorraine, Oommen, Nikhil Babu, Carreira, Suzanne, Drake, Charles G, Jones, Robert, Cooper, Colin S, Scher, Howard I, de Bono, Johann S · 2012 · The Lancet Oncology
Cited by 112

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary Background Biomarkers are urgently needed to dissect the heterogeneity of prostate cancer between patients to improve treatment and accelerate drug development. We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome. Methods Whole blood was collected into PAXgene tubes from patients with castration-resistant prostate cancer and patients with prostate cancer selected for active surveillance. In stage I (derivation set), patients with castration-resistant prostate cancer were used as cases and patients under active surveillance were used as controls. These patients were recruited from The Royal Marsden Hospital NHS Foundation Trust (Sutton, UK) and The Beatson West of Scotland Cancer Centre (Glasgow, UK). In stage II (validation-set), patients with castration-resistant prostate cancer recruited from the Memorial Sloan-Kettering Cancer Center (New York, USA) were assessed. Whole-blood RNA was hybridised to Affymetrix U133plus2 microarrays. Expression profiles were analysed with Bayesian latent process decomposition (LPD) to identify RNA expression profiles associated with castration-resistant prostate cancer subgroups; these profiles were then confirmed by quantative reverse transcriptase (qRT) PCR studies and correlated with overall survival in both the test-set and validation-set. Findings LPD analyses of the mRNA expression data divided the evaluable patients in stage I (n=94) into four groups. All patients in LPD1 (14 of 14) and most in LPD2 (17 of 18) had castration-resistant prostate cancer. Patients with castration-resistant prostate cancer and those under active surveillance comprised LPD3 (15 of 31 castration-resistant prostate cancer) and LDP4 (12 of 21 castration-resistant prostate cancer). Patients with castration-resistant prostate cancer in the LPD1 subgroup had features associated with worse prognosis and poorer overall survival than patients with castration-resistant prostate cancer in other LPD subgroups (LPD1 overall survival 10.7 months [95% CI 4.1–17.2] vs non-LPD1 25.6 months [18.0–33.4]; p<0.0001). A nine-gene signature verified by qRT-PCR classified patients into this LPD1 subgroup with a very low percentage of misclassification (1.2%). The ten patients who were initially unclassifiable by the LPD analyses were subclassified by this signature. We confirmed the prognostic utility of this nine-gene signature in the validation castration-resistant prostate cancer cohort, where LPD1 membership was also associated with worse overall survival (LPD1 9.2 months [95% CI 2.1–16.4] vs non-LPD1 21.6 months [7.5–35.6]; p=0.001), and remained an independent prognostic factor in multivariable analyses for both cohorts. Interpretation Our results suggest that whole-blood gene profiling could identify gene-expression signatures that stratify patients with castration-resistant prostate cancer into distinct prognostic groups. Funding AstraZeneca, Experimental Cancer Medicine Centre, Prostate Cancer Charity, Prostate Cancer Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70372-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 112

Metadata

Authors
Olmos, D., Brewer, D., Clark, J., Danila, D. C., Parker, C., Attard, G., Fleisher, M., Reid, A. H., Castro, E., Sandhu, S. K., Barwell, L., Oommen, N. B., Carreira, S., Drake, C. G., Jones, R., Cooper, C. S., Scher, H. I., & de Bono, J. S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-11
Volume
13
Issue
11
Pages
1114-1124
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2153641732
Cited by
112
References
3
FWCI
11.86
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70372-8
The paper
Olmos, D., Brewer, D., Clark, J., Danila, D. C., Parker, C., Attard, G., Fleisher, M., Reid, A. H., Castro, E., Sandhu, S. K., Barwell, L., Oommen, N. B., Carreira, S., Drake, C. G., Jones, R., Cooper, C. S., Scher, H. I., & de Bono, J. S. (2012). Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70372-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.